Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study

Exclusion Criteria

• •Previous identified allergy or hypersensitivity to any component of the study treatment
• •Allergies to eggs, egg products, soybeans, or soy products
• •Personal or first degree relative with a history of malignant hyperthermia
• •Has a known additional malignancy that is expected to require active treatment within two years, or is likely to be life-limiting in the opinion of the treating investigator. Superficial bladder cancer, non-melanoma skin cancers, or low-grade prostate cancer not requiring therapy would not exclude participation in this trial.
• •Uncontrolled intercurrent illness including, but not limited to: Symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Pregnant or lactating females
• •* Patients who undergo reoperation during their initial hospitalization will be censored at the time of reoperation.
• •Prisoner status